BioNTech SE (BNTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BioNTech SE (BNTX)
Company Performance

Current Price

as of Dec 03, 2024

$115.59

P/E Ratio

N/A

Market Cap

$27.71B

Description

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Metrics

Overview

  • HQMainz, RP
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBNTX
  • Price$115.59-1.37%

Trading Information

  • Market cap$27.71B
  • Float99.88%
  • Average Daily Volume (1m)1,136,553
  • Average Daily Volume (3m)1,137,547
  • EPS-$2.10

Company

  • Revenue$3.30B
  • Rev growth (1yr)40.41%
  • Net income$217.62M
  • Gross margin85.63%
  • EBITDA margin32.90%
  • EBITDA$449.85M
  • EV$10.67B
  • EV/Revenue3.23
  • P/EN/A
  • P/S8.57
  • P/B1.30
Documents
Factset Street Account
Pfizer and BioNTech announce topline data for mRNA-based combination vaccine program against influenza and COVID-19 ($95.25, 0.00) (2023-10-26T10:49:59Z)
BioNTech reports Q3 net income €160.0M vs FactSet €107.3M [7 est, (€649)-851.8M] ($95.78, 0.00) (2023-11-06T11:59:57Z)
BioNTech presents positive Phase 1/2 data update for CAR-T cell therapy candidate BNT211 in advanced solid tumors at ESMO Congress 2023 ($91.75, +0.84) (2023-10-23T15:35:53Z)
BioNTech downgraded to underweight from neutral at JPMorgan ($100.41, 0.00) (2023-12-01T11:06:13Z)
BioNTech acquires startup AexeRNA; terms undisclosed -- Endpoints News ($96.89, +4.40) (2023-11-03T18:32:19Z)
Wikipedia
BioNTech_SE
Earnings Calls
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-06)
Earnings Report (2023-08-07)
Factset
Factset Business Description